Burosumab improves physical function, reduces pain in X-linked hypophosphatemia

CHICAGO — Burosumab is tied to greater improvements in pain, stiffness and physical function than active vitamin D and phosphate salts among patients with X-linked hypophosphatemia, according to data presented at ENDO 2026. Burosumab-twza (Crysvita, Kyowa Kirin), a monoclonal anti-fibroblast growth factor 23 antibody, was approved by the FDA as the first therapy to treat X-linked